NTX-1088

Nectin Therapeutics Ltd · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	NTX-1088
Sponsor	Nectin Therapeutics Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NTX-1088 CI brief — competitive landscape report
NTX-1088 updates RSS · CI watch RSS
Nectin Therapeutics Ltd portfolio CI